[Skip to Content]
[Skip to Content Landing]

Conference Commentary: Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial

Diederik Gommers, MD, PhD, of Erasmus University in Rotterdam, the Netherlands, comments on the findings of a trial reporting no difference in 28-day mortality among patients with septic shock and high endotoxin activity randomized to polymyxin B hemoperfusion treatment plus conventional medical therapy vs sham treatment plus conventional medical therapy. Comments were made at the European Society of Intensive Care Medicine (ESICM) 31st Annual Congress, LIVES 2018, on October 24 in Paris. Used with permission.

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Name Your Search

Save Search

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

Topics
State Requirements